Disease Overview：Hypoglycemia（HG）
Hypoglycemia, defined as abnormally low plasma glucose concentration—typically below 70 mg/dL (3.9 mmol/L)—is a potentially life-threatening endocrine disorder commonly associated with insulin or sulfonylurea therapy in diabetes mellitus, but also arising from insulinoma, adrenal insufficiency, pituitary dysfunction, or critical illness. Symptoms range from autonomic manifestations (tremor, palpitations, diaphoresis) to neuroglycopenic signs (confusion, behavioral changes, seizures, or coma), necessitating prompt diagnosis and individualized management. Accurate etiological evaluation requires dynamic testing—including mixed-meal tolerance tests, fasting studies, and selective arterial calcium stimulation—alongside advanced imaging such as contrast-enhanced MRI or 68Ga-DOTATATE PET/CT for insulinoma localization.
China offers distinct advantages in hypoglycemia care: its leading endocrinology centers—such as Peking Union Medical College Hospital and Shanghai Jiao Tong University Affiliated Sixth People’s Hospital—boast nationally certified multidisciplinary teams with deep expertise in rare endogenous hyperinsulinemic disorders. State-of-the-art diagnostic platforms, including real-time continuous glucose monitoring (CGM) integration and high-resolution pancreatic MRI protocols, support precise phenotyping. Clinical outcomes reflect this capability: over 92% surgical cure rates for benign insulinomas and robust medical management protocols for congenital hyperinsulinism. Treatment costs remain significantly lower than in the US or Western Europe—often 40–60% less for comprehensive workup and intervention—without compromising evidence-based standards. As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying hospital credentials, coordinating specialist consultations, providing itemized, transparent pricing, and delivering end-to-end support—from visa assistance and accommodation to post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hypoglycemia (Endocrinology Department)
Non-Surgical / Conservative / Medication Management
*Target Criteria:* Symptomatic reactive or fasting hypoglycemia, insulinoma (pre-op stabilization), drug-induced (e.g., sulfonylurea overdose), or functional hypoglycemia without structural cause.
- •Initial Diagnostic Workup
- Continuous Glucose Monitoring (CGM, 14-day system with sensor + reader + analysis report): $320–$410 - Oral Glucose Tolerance Test (OGTT) with insulin/C-peptide sampling at 0/30/60/120/180 min: $110–$145
- •Pharmacologic Therapy
- Octreotide LAR (monthly intramuscular injection, 3 doses): $1,280–$1,650 - Glucagon emergency kit (2-dose): $45–$60
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Confirmed insulinoma (via CT/MRI + selective arterial calcium stimulation test), non-resectable metastatic disease (for palliative embolization), or refractory nesidioblastosis in pediatric cases.
- •Preoperative Evaluation
- Selective Arterial Calcium Stimulation (SACS) test with hepatic vein sampling: $1,150–$1,480 - Endoscopic Ultrasound (EUS) with fine-needle aspiration (FNA): $420–$540
- •Definitive Procedures
- Distal pancreatectomy (≥2 cm or multifocal): $6,900–$8,700 - Transarterial Embolization (TAE) for unresectable/metastatic insulinoma: $5,300–$6,800
Special / Complex Condition Management
- •Congenital Hyperinsulinism (CHI) in infants: Diazoxide + octreotide + glucagon infusion + genetic testing (ABCC8/KCNJ11 panel): $2,100–$2,850 (initial 4-week inpatient stabilization).
- •Post-bariatric hypoglycemia (nPOG): Medical nutrition therapy + acarbose + GLP-1 receptor antagonist (semaglutide 0.25 mg weekly × 8 wks): $1,020–$1,350.
- •Autoimmune Hypoglycemia (anti-insulin antibodies): High-dose corticosteroids + rituximab (2 infusions): $3,400–$4,200.
Quick Selection Guide
- •Elderly (>75 yrs), mild reactive hypoglycemia, limited budget: CGM + dietary counseling + diazoxide ($415–$575 total)
- •Adult, confirmed solitary insulinoma, no comorbidities: SACS + laparoscopic enucleation ($6,300–$8,000 total)
- •Child with suspected CHI, family history: Genetic panel + inpatient diazoxide/octreotide trial ($2,100–$2,850)
- •Metastatic insulinoma, poor surgical candidacy: TAE + octreotide LAR ($6,600–$8,500)
- •Severe recurrent hypoglycemia with cognitive impairment: Urgent CGM + glucagon pump initiation + endocrinology consult ($780–$1,020)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hypoglycemia Medical Vacation Packages
Curated transparent all-inclusive packages combining Hypoglycemia treatment with China top medical destinations:
